Announcements

Per the Guidelines and Guidance (G&G) Committee process for guidance manuscripts, draft manuscripts go through a public comment period and G&G Committee review and approval before submitting the manuscript to the Journal of Thrombosis and Haemostasis (JTH).

The G&G Committee would like to announce that the guidance manuscript titled, "Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: Guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis," is now open for public comment. Note: This manuscript is confidential and in draft form.

Please click here to submit your comments by Wednesday, November 12, 2025.

Per the Guidelines and Guidance (G&G) Committee process for guidance manuscripts, draft manuscripts have to go through a public comment period and Committee review and approval before submitting the manuscript to the Journal of Thrombosis and Haemostasis (JTH).

The G&G Committee would like to announce that the guidance manuscript titled, "Development of New Antithrombotic Drugs for Children (Part 1): Guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group," is now open for public comment. Note: This manuscript is confidential and in draft form.

Please click here for a link to the guidance and to submit your comments by Thursday, October 30, 2025.

Dear colleagues:

As part of the "Assessment of methods of documentation & reporting of ABR in clinical trials" project, we have drafted recommendations for standardizing ABR.

We now invite you to collect feedback of the proposed standardization from your communities, and to submit your comments over the upcoming month.

Please submit any comments to Alok Srivastava at asriv@haematology.in or respond directly to the discussion board post in the myISTH community forum.

Dear Colleagues,

You are invited to participate in a research survey titled "SCOPE TXA: Sickle Cell Observations of Provider Experiences with Tranexamic Acid." This study is being conducted by researchers at Central Michigan University and the Children's Hospital of Michigan. The purpose of this survey is to gather insights from providers across various specialties who care for patients with sickle cell disease. We are particularly interested in understanding the clinical scenarios in which tranexamic acid (TXA) has been used, how dosing is managed, and any considerations or hesitations providers may have regarding its use in this unique patient population.

Even if you have not personally used TXA in patients with sickle cell disease, we are still very interested in your perspectives on the potential use of this medication in relevant clinical situations.

Key details:

· Estimated time to complete: 5–10 minutes

· Confidentiality: Responses will remain confidential

· Voluntary Participation: Participation is entirely voluntary and anonymous

· IRB Approval: Central Michigan University IRB has approved this study

· Compensation: Participants who complete the survey may choose to enter a drawing to win one of ten $50.00 gift cards. Gift cards will be delivered via mail.

Your insights will help inform future clinical guidance and promote safe, evidence-informed care for individuals living with sickle cell disease.

Please only complete the survey once, even if you receive it through multiple channels.

https://redcap.cmich.edu/surveys/?s=7MFD9LP7FAKPXPAX

If you have any questions, please do not hesitate to contact the principal investigator, Dr. Gianna Guzzardo Valenti, at Valen4g@cmich.edu or (313) 745-5515.

Thank you for your time and valuable input. You can find more information about the study here:  SCOPE TXA_Research Information Sheet.docx

Sincerely,

Gianna Guzzardo Valenti, MD

Children's Hospital of Michigan

Dear Colleagues,

You are invited to participate in a research survey titled "SCOPE TXA: Sickle Cell Observations of Provider Experiences with Tranexamic Acid." This study is being conducted by researchers at Central Michigan University and the Children's Hospital of Michigan. The purpose of this survey is to gather insights from providers across various specialties who care for patients with sickle cell disease. We are particularly interested in understanding the clinical scenarios in which tranexamic acid (TXA) has been used, how dosing is managed, and any considerations or hesitations providers may have regarding its use in this unique patient population.

Even if you have not personally used TXA in patients with sickle cell disease, we are still very interested in your perspectives on the potential use of this medication in relevant clinical situations.

Key details:

· Estimated time to complete: 5–10 minutes

· Confidentiality: Responses will remain confidential

· Voluntary Participation: Participation is entirely voluntary and anonymous

· IRB Approval: Central Michigan University IRB has approved this study

· Compensation: Participants who complete the survey may choose to enter a drawing to win one of ten $50.00 gift cards. Gift cards will be delivered via mail.

Your insights will help inform future clinical guidance and promote safe, evidence-informed care for individuals living with sickle cell disease.

Please only complete the survey once, even if you receive it through multiple channels.

https://redcap.cmich.edu/surveys/?s=7MFD9LP7FAKPXPAX

If you have any questions, please do not hesitate to contact the principal investigator, Dr. Gianna Guzzardo Valenti, at Valen4g@cmich.edu or (313) 745-5515.

Thank you for your time and valuable input. You can find more information about the study here:  SCOPE TXA_Research Information Sheet.docx

Sincerely,

Gianna Guzzardo Valenti, MD

Children's Hospital of Michigan

The ISTH would like to invite members to submit any comments for the draft guidance on the Surgical and Procedural Bleed Risk Stratification: Guidance for Anticoagulated Patients Undergoing Planned Surgery. 

The manuscript is confidential and in draft form and should not be forwarded.

Please click here to submit your comments by Monday, September 1, 2025.

Kindly email Andrea Hickman at andrea_hickman@isth.org if you have any questions or concerns.

We are writing to invite your institution to participate in a multicenter retrospective cohort study titled:

"PAUSE CAT" [Perioperative Anticoagulation Use and Suspension Evaluation in Cancer-Associated Thrombosis]

This collaborative project aims to better understand thrombotic and bleeding outcomes in patients with newly diagnosed cancer-associated thrombosis undergoing procedures requiring temporary anticoagulation interruption.

Study Highlights:

Design: Retrospective chart review via EMR
Inclusion: Adults with active malignancy and new VTE undergoing a procedure within 30 days of VTE diagnosis
Outcomes: Recurrent VTE, embolic events, bleeding complications, and mortality within 6 months
Data Collection: Standardized REDCap form
Site Requirements: Local IRB approval and data use agreement

This study represents a valuable opportunity to advance our understanding of real-world anticoagulation complications in high-risk oncology populations, and we hope to include a diverse cohort of institutions.

If your team is interested in participating or would like more information, please don’t hesitate to reach out. We would be happy to set up a meeting to discuss logistics and next steps.

Avi Leader

Memorial Sloan Kettering Cancer Center

leadera@mskcc.org

Rushad Patell

Beth Israel Deaconess Medical

Centerrpatell@bidmc.harvard.edu

Greetings, esteemed doctors and scientists. Your participation in the Standardization of Laboratory Assays to Measure FXII/FXIIa survey is being requested.

This survey aims to collect information across SSC members on FXII methodology with the goal of optimizing and streamlining the best practices to measure FXII zymogen and protease levels. The survey's specific aims include:

• Create a database to evaluate current practice in research involving FXII among researchers in the field of thrombosis and hemostasis.
• Conduct exploratory and validation assays to harmonize FXII measurements.
• Establish consensus guidance on the design and execution of laboratory tests to measure FXII antigen and activity.

Your participation is greatly appreciated. 

You may open the survey in your web browser by clicking the link below:
SSC Project - Standardization of laboratory assays to measure FXII antigen and activity.

If the link above does not work, try copying the link below into your web browser:
https://redcap.isth.org/surveys/?s=FRJF7L37F7KDXPR7

Greetings: we are inviting clinicians to participate in an electronic survey on global perioperative anticoagulation management practices. The survey will take approximately 15 minutes to complete.

It is hoped that any research output will benefit the standardisation of perioperative anticoagulation management and promote the uptake of Anticoagulation Stewardship internationally.

You will not need to have experience with Antithrombotic Stewardship or Anticoagulation Stewardship to complete the survey.

If you wish to participate in the survey or find out more information, please click here.

We are also contactable anytime via email should you require any further information at: julianne.chong@health.nsw.gov.au.

Greetings, we are inviting clinicians to participate in an electronic survey on global perioperative anticoagulation management practices. The survey will take approximately 15 minutes to complete.

It is hoped that any research output will benefit the standardisation of perioperative anticoagulation management and promote the uptake of Anticoagulation Stewardship internationally.

You will not need to have experience with Antithrombotic Stewardship or Anticoagulation Stewardship to complete the survey.

If you wish to participate or find out more information, please click here.

We are also contactable anytime via email should you require any further information at: julianne.chong@health.nsw.gov.au.

The ISTH SSC Subcommittees on Platelet Physiology and Platelet Immunology has recently drafted an SSC Communication on the preferences of aggregometry for platelet function testing in thrombocytopenic patients after reviewing results of a survey regarding pre-analytical, analytical, post-analytical and performance aspects. 

Please follow the link below to review and provide your comments by July 4, 2025.

The ISTH would like to invite members to submit any comments for the draft guidance on the management of women with type 2B von Willebrand Disease during pregnancy and postpartum. 

The manuscript is confidential and in draft form and should not be forwarded.

Please click here to submit your comments by Monday, June 30, 2025.

Kindly email Andrea Hickman at andrea_hickman@isth.org if you have any questions or concerns.

The ISTH would like to invite members to submit any comments for the draft guidance on the management of women with type 2B von Willebrand Disease during pregnancy and postpartum. 

The manuscript is confidential and in draft form and should not be forwarded.

Please click here to submit your comments by Monday, June 30, 2025.

Kindly email Andrea Hickman at andrea_hickman@isth.org if you have any questions or concerns.

Dear Colleague,

We invite you to participate in this international survey aimed at assessing the current state of joint ultrasound practice in hemophilia care worldwide. This initiative is part of an ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders project: Standardization of musculoskeletal ultrasound in hemophilia and related disorders.

By collecting data on clinical usage patterns, professional roles, access to equipment, training levels, and perceived barriers, the study seeks to identify unmet needs across diverse healthcare settings.

The findings will help lay the foundation for future collaborative efforts to improve access to training and to support the standardized, evidence-based use of ultrasound in hemophilia management globally.

All healthcare professionals involved in hemophilia care at the treatment center - including physicians, physical therapists, and allied health professionals - are invited to complete the survey, regardless of whether joint ultrasound is currently used at their center. Gathering input from a range of professional roles will help capture multiple perspectives on the use of musculoskeletal ultrasound, reflecting the multidisciplinary nature of hemophilia care. Your insights, whether based on direct experience or lack of access, are equally important in shaping future clinical and educational strategies.

Thank you for contributing to this important initiative.

Arterial thrombosis (acute coronary syndrome or stroke) in Glanzmann Thrombasthenia (GT) patients poses a major clinical challenge. These rare but serious events are extremely difficult to manage, given the inherent bleeding risk in GT and the absence of evidence-based therapeutic guidelines. Available data are limited to a few case reports, and the heterogeneity of hemostatic strategies highlights the urgent need for standardized recommendations.

To address this gap, the GlanzArter project aims to retrospectively analyze an international cohort of adult GT patients who have experienced an arterial thrombotic event, including acute coronary syndrome or stroke. The study will describe patients' demographic and biological characteristics, cardiovascular risk factors, diagnostic procedures, hemostatic and interventional management, and outcomes, including bleeding complications. This is an official collaborative project of the ISTH SSC Subcommittee on Platelet Physiology.

The ultimate goal is to identify critical patterns and management strategies that may inform future guidelines for the care of GT patients facing arterial thrombotic events.

We are conducting a retrospective data collection through two structured CRFs (one for acute coronary syndrome, one for stroke). These have been developed by an expert panel in hemostasis, cardiology, and neurology. All data will be pseudonymized and stored in a secured database hosted by Marseille University Hospital (France).

We are now inviting all centers involved in the care of GT patients worldwide to contribute by reporting any case of stroke, transient ischemic attack, acute coronary syndrome, or unstable angina in adult GT patients. Even a single case per center is highly valuable due to the rarity of the condition.

Your participation is essential to help improve the care of these vulnerable patients.

To receive the protocol and CRFs, as well as further information please contact Prof. Paul Saultier (paul.saultier@ap-hm.fr). (See full project description under "Current Projects" on the ISTH website.)

The ISTH would like to invite members to submit any comments for the draft recommendations of the focused update of the treatment of thrombotic thrombocytopenic purpura (TTP) guidelines. 

These draft recommendations are confidential and in draft form and should not be forwarded.

Please click here to submit your comments by Wednesday, March 19, 2025.

Kindly email Andrea Hickman at andrea_hickman@isth.org if you have any questions or concerns.

Date & Time: March 3 at 11 am EST/ 16 UTC

In honor of blood clot awareness month, the ISTH, RPTH & World Thrombosis Day present a webinar on "Health Literacy in Pediatric Thrombosis: A Landscape Analysis." Hear from two of the study's authors, Laura Avila and Jennifer Vincelli. Mara Nuñez Toscano, WTD Steering Committee member, and Marisol Betensky, ISTH member, will moderate this insightful conversation.

The Platelet Immunology Scientific Standardization Committee of the ISTH invites you to participate in the "Survey of Practices regarding Heavy Menstrual Bleeding in Immune Thrombocytopenia". This survey aims to identify knowledge gaps in clinical care for individuals with immune thrombocytopenia (ITP) at risk for heavy menstrual bleeding. Additionally, we aim to study the impact of therapies, effect of health-related quality of life and underlying pathophysiology of heavy menstrual bleeding in ITP.  We appreciate your participation in this survey.

Best wishes,

Ruchika Sharma, MD, University of Texas Southwestern Medical Center

Michele Lambert, MD, Children's Hospital of Philadelphia

Megan Brown, MD, Children's Healthcare of Atlanta